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Abstract
Background: Natural health products (NHPs), such as herbal medicines and vitamins, are widely available over-the-
counter and are often purchased by consumers without advice from a healthcare provider. This study examined
how consumers respond when they believe they have experienced NHP-related adverse drug reactions (ADRs) in
order to determine how to improve current safety monitoring strategies.
Methods: Qualitative semi-structured interviews were conducted with twelve consumers who had experienced a
self-identified NHP-related ADR. Key emergent themes were identified and coded using content analysis
techniques.
Results: Consumers were generally not comfortable enough with their conventional health care providers to
discuss their NHP-related ADRs. Consumers reported being more comfortable discussing NHP-related ADRs with
personnel from health food stores, friends or family with whom they had developed trusted relationships. No one
reported their suspected ADR to Health Canada and most did not know this was possible.
Conclusion: Consumers generally did not report their suspected NHP-related ADRs to healthcare providers or to
Health Canada. Passive reporting systems for collecting information on NHP-related ADRs cannot be effective if
consumers who experience NHP-related ADRs do not report their experiences. Healthcare providers, health food
store personnel, manufacturers and other stakeholders also need to take responsibility for reporting ADRs in order
to improve current pharmacovigilance of NHPs.
Background
Despite the belief that herbal medicine and other natural
health products (NHPs) are safe [1], these products are
pharmacologically active and therefore have inherent
risk. Under Canadian federal regulations, NHPs are
technically a sub-category of drugs. Any substance natu-
rally found in plants, animals, fungi, algae or micro-
organisms (regardless of the source used for the supple-
m e n t )t h a ti su s e dt od i a g n o s e ,t r e a to rp r e v e n td i s e a s e
and is suitable for self-care use is categorized as a NHP
in Canada. This category includes vitamins (regardless
of source), minerals, traditional Chinese medicines,
Ayurvedic medicines, Native North American medicines,
traditional herbal remedies and homeopathic medicines.
Biologics such as insulin, tobacco and marijuana are
specifically excluded from the NHP definition [2]. Sev-
eral reviews clearly document that NHPs, especially
herbal medicines, are associated with adverse drug reac-
tions (ADRs) (See Table 1: ADR Definitions) [3,4]. The
need to understand ADRs associated with NHPs is
increasingly important, given that over 60% of all North
Americans report using some form of complementary
and alternative medicine (CAM) (including herbal medi-
cines) in the management of their health [1,5]. In
Canada, 7 in 10 adults have ever used an NHP [1].
Although NHPs are commonly used, relatively little is
known about the frequency of NHP-related suspected
ADRs. In Canada, Health Canada collects reports of sus-
pected ADRs from healthcare professionals, and from
consumers, about NHPs (and conventional drugs)
through the Canada Vigilance Program [6]. Similar sys-
tems exist in many developed and developing countries,
and the World Health Organization’s Collaborating
Centre for International Drug Monitoring co-ordinates
global ADR data and searches for signals of safety con-
cerns. Under-reporting is a challenge of such passive
reporting systems [7]. Notwithstanding the problems in
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known avenue for reporting and feedback loops to prac-
titioners and, to some extent, consumers. However,
experiences of (and the incidence of) herbal medicine-
related ADRs are more difficult to determine because
under-reporting of suspected ADRs, may be more sub-
stantial for NHPs than for conventional drugs [8].
One of the reasons for under-reporting of NHP-
related ADRs may be that many consumers believe
NHPs are safe because they originate from natural
ingredients [1]. Consumers frequently self-prescribe
NHPs, without the advice of a qualified health provider
[9]. Increasing consumerism, an environment in which
individuals are taking their health matters into their
own hands, partly explains this [10]. Instead of passively
following the advice of health providers, individuals
explore opinions and advice from a range of information
sources (e.g., such as the internet, friends and family)
and increasingly challenge healthcare practitioners with
questions about treatments [11].
In Canada, NHPs are regulated as a sub-category of
drugs. By definition, they are available over-the-counter
and include such products as herbal medicines, vitamins
and homeopathic preparations. Since NHPs are non-
prescription medicines, in order to capture safety-related
information NHP-related ADRs must be reported by
consumers: consumers must either inform healthcare
professionals, who are then encouraged to file an official
report, or consumers may directly inform Health
Canada. If these steps are not taken, the ADR is not
likely to be captured by the national reporting system.
Since many consumers self-prescribe NHPs, it is per-
haps not surprising that consumers appear less likely to
report ADRs associated with NHPs to their healthcare
providers than those associated with conventional over-
the-counter drugs [12]. Even where consumers inform
healthcare professionals of suspected ADRs associated
with NHPs, these reports may not be filed with the
Canadian Vigilance Program (Health Canada’sA D R
reporting system) [13].
If natural health products have potential deleterious
effects both on their own and in combination with other
drugs, then they also need to be monitored. Yet the cur-
rent systems are ineffective. The purpose of this study was
to explore how users of NHPs identify and respond to
NHP-related suspected ADRs. Specifically, the study
examined the experiences of consumers who had experi-
enced what they believed to be an NHP-related ADR and
their reasons for choosing to report (or not report) their
reactions. This information is crucial in order to better
understand why NHP-related ADRs are so rarely reported.
Methods
This was an exploratory descriptive qualitative study.
Qualitative methods were best suited for this study
because although under-reporting is a well-known weak-
ness of passive surveillance systems, it is not at all clear
how consumers react when they believe they have experi-
enced an ADR or why they do what they do. Additionally,
NHPs constitute a highly contextualized category of
medicines, in that they have their own unique classifica-
tion and perceptions associated with them. The methods
chosen allowed exploration of the idiosyncrasies asso-
ciated with this topic. In-depth semi-structured inter-
views were conducted from September 2007 to
December 2007 with NHP consumers who had experi-
enced a self-identified suspected ADR associated with
use of an NHP within the past 5 years. Inclusion criteria
for participants were: have experienced a suspected ADR
that they perceived to be associated with an NHP in the
past 5 years; able to participate in an interview in English;
gave informed consent to participate. While we had no
way to determine if an ADR had actually occurred, the
participant’s perception of an NHP-related ADR was the
key inclusion criterion because the purpose of the study
was to examining their experiences and behaviours in
response to this perceived event.
The participants were recruited primarily from the
Greater Toronto area. Some consumers also volunteered
to participate from Ottawa and Vancouver as they became
aware of the study from their social networks. Participants
were recruited through posters and advertisements in sev-
eral university email listservs, online networking groups
such as facebook, health food stores, pharmacies and
Table 1 ADR Definitions
Term Definition
Adverse Drug
Reaction (ADR)
A noxious and unintended response to a drug,
and which occurs at doses normally used in
persons for the prophylaxis, diagnosis, or therapy
of disease, or for the modification of physiological
function.
Suspected ADR An adverse event that for which there is a
suspicion of a causal relationship with a drug
Adverse event/
experience
Any untoward medical occurrence that may
present during treatment with a pharmaceutical
product but which does not necessarily have a
causal relationship with this treatment.
Serious ADR Fatal, life threatening (such as liver failure,
abnormal heart rhythms, certain types of allergic
reactions), result in persistent or significant
disability or incapacity, require or prolong
hospitalization, are congenital anomalies or birth
defects, or are otherwise medically important.
Severe ADR Severity describes the intensity of the adverse
event or ADR. A severe ADR (e.g., a severe
headache) is not necessarily a serious ADR
￿ World Health Organization Upsalla Monitoring Centre: The Global
Intelligence Network for Benefits and Risk in Medicinal Products
http://www.who-umc.org/ Accessed on: Feb 8, 2010
￿ World Health Organization: Note for guidance on clinical safety data
management: definitions and standards for expedited reporting. 1995.
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sample of individuals referred by the study team’s exten-
sive professional and social networks. In addition, snowball
sampling (in which participants were asked to identify
other potential participants within their social circles) was
employed to extend the sample [14]. The recruitment ads
requested that anyone who had experienced what s/he
believed to be an NHP-related ADR call the study centre.
Callers were screened to ensure they met the inclusion cri-
teria. Every effort was made to recruit a maximum varia-
tion sample with a range of sociodemographic
backgrounds by placing recruitment materials in a wide
range of locations; however, given the difficulty we
encountered in finding people that identified experiencing
a NHP-related ADR, all those who met the inclusion cri-
teria for the study were interviewed.
All interviews were conducted by RW after written
informed consent was obtained. Interviews were based on
a semi-structured interview guide derived from the collec-
tive experience of the authors and a review of the litera-
ture (see Table 2: Questions for Consumer Guided
Interview). Interviews lasted approximately 30-60 minutes
and took place at a private location most convenient to
the participant (e.g., participant’s home, in the researcher’s
office). All interviews were audio-recorded so that the ver-
batim transcriptions and field notes could be coded. Field
notes were hand-written during and immediately following
the interviews.
Two independent coders used a constant comparison
method of content analysis to identify key themes in the
interviews [15]. Disagreement was resolved through in-
depth discussion. A software program, NVIVO 7, was
used to organize and apply coding to the data [16]. Data
analysis and coding took place throughout the process
of data collection. The interview guide was updated and
modified after the first couple of coding sessions to
allow for increasingly detailed data collection in key
emerging themes.
Interviewing continued until theoretical saturation of
the key themes was achieved [14]. Saturation is defined
as the point at which no new information or themes
emerge from the data [14,17]. In this study, saturation
was identified in themes related to why people did or
did not tell anyone about the NHP-related suspected
ADR after approximately 10 interviews. Two additional
interviews were completed to confirm that saturation
had been achieved.
Ethics approval for this study was granted by the
Research Ethics Board at the University of Toronto. All
personal identifiers have been removed or disguised so
the person(s) described are not identifiable.
Results
Participants varied in age and demographic background
(see Table 3: Participant Demographics) and had experi-
enced a range of different NHP-related suspected ADRs
such as rash, nausea, digestive disturbance and anxiety/
irritability. The final sample was predominantly female
and highly educated, although efforts were made to
recruit more males and participants from different
Table 2 Questions for Consumer Guided Interview
1. What prompted you to take this natural health product?
2. Where did you purchase your product? (e.g. Health food store? Pharmacy? Internet? Other?)
3. Is this where you usually buy your natural health products? Why do you buy them from there?
4. Can you describe what (side effect) happened to you? How soon after you took the product did it happen? How severe was it? Exactly what
symptoms did you experience?
5. What did you do about it? Why?
a. Did you tell anyone (and why or why not)? If your side effects were more mild/moderate/severe, would you have responded differently?
6. Do you think that people should report their side effects? Why or why not?
a. Where would be an appropriate place to report? Medical Doctor, Pharmacist, Naturopath, Retail store where they bought it, Manufacturer,
Media, Other.
7. What kinds of side effects do you think should be reported?
8. What would prompt you to report (or not report) a side effect?
9. What do you think about the safety of natural health products in general?
a. How safe did you think the product you took was before you used it?
10. Where do you get information about natural health products? Why that source?
11. Are you familiar with the reporting system for adverse drug reactions in Canada (describe)? What do you know about it? Have you ever used it?
What for? (e.g. To send in a report? Or to look at the reports that other people have made?)
12. What do you think are the major obstacles in reporting side effects from a natural health product?
13. Are you satisfied with the current procedure of adverse event reporting system for natural health products? Why or why not?
a. Has Health Canada and/or your health practitioner provided any information, assistance, or feedback to you about reporting procedures?
b. What can be done to enable reporting of side effects from natural health products?
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experienced by the participants in this study were non-
serious (i.e., did not require hospitalization or lead to
permanent disability or death), but differed in perceived
degree of severity from mild to moderate to severe (see
Table 4: Participant Reactions and Behaviours).
Although Health Canada accepts direct reporting of
suspected NHP-related ADRs by consumers, the partici-
pants did not seem to know that was an option. The
only ones who were aware of their ability to indepen-
dently report their suspected ADRs were told this by
their health providers, or personally had some kind of
health care training and, therefore, had been exposed to
the reporting scheme through their professions.
The main themes that emerged from this research
were: 1) how participants first identified their suspected
ADRs; 2) how they associated the reaction with their
NHP treatments; 3) what influenced their likelihood of
reporting the suspected ADR to health care providers,
the Canadian Vigilance Program, or anyone else; 4) bar-
riers and enablers to reporting.
Identifying the suspected ADR as NHP-related
Once they had experienced ADRs, the consumers first had
to identify that they were in fact ADRs and not just new
illnesses or worsening of pre-existing conditions. Consu-
mers tended to use a process of elimination, re-challenge
and investigative reasoning to evaluate their symptoms.
I was trying to think back to all the things I’d eaten
the day before. I took, like maybe two, two addi-
tional ones and like within an hour the rash had
spread ... and that’s when I was like, oh, it must be
this new product! (Consumer 1)
I had never experienced anything like that before.
(Consumer 6)
T h e r eh a dt ob eac h a n g ew i t h i nm yd i e to rm yl i f e -
style or something to trigger this headache... I kind
of know when something might be different or
changing so I knew, I just felt that this migraine was
triggered by the medication. I can’t see it being any-
thing else. (Consumer 9)
Most participants chose to consume the NHPs that
they associated with suspected ADRs without advice or
monitoring from a healthcare provider. Thus, when they
experienced the suspected ADR, they felt obliged to take
responsibility to interpret the reaction on their own.
Participants reported methodically evaluating their reac-
tions in order to determine the purported cause. They
generally came to the conclusion that the symptoms
they were experiencing were related to the NHP after
considering the possibility of alternative explanations for
the symptoms. For example, they ruled out changes in
lifestyle, behaviour or other medication, and also based
their decision on criteria such as the temporal proximity
of ingestion of the product to the reaction, by trying a
different brand of the product and, in some cases, stop-
ping (de-challenge) and then re-starting (re-challenge)
the product suspected of causing the reaction:
Question: How did you decide that it was the pro-
duct that caused these things?
Ig u e s sb e c a u s eI ’d never taken it before.... that was
the only thing I could attribute it to. (Consumer 12)
From using one brand and then switching to
another, the fact that they were different brands but
they were the same ingredients I was using. They
contained the same things. I was just trying another
brand and I was still getting the same symptoms and
then I also linked it because just at this time when I
was taking it, I wasn’t taking any other products at
that time. (Consumer 4)
In o t i c e di fIs k i p p e di t ,l i k eIf o r g o t– it’sl u n c ho r
something - then I didn’t have the symptoms ... so,
yah, that was a clue. (Consumer 5)
I would take it and about within an hour, I would
start to feel nauseous (Consumer 10)
I think because other people developed it and the
only thing we had in common was we took this pro-
duct. (Consumer 2)
I had some, you know a little bit later. The same
thing happened and so I put two and two together.
(Consumer 6)
When you’re dealing with something that’s given for
dieting you sort of know that there’s a chance that it
might be something that it shouldn’t be and so I just
f i g u r e dt h a tt h a tw a sp r o b a b l ys o m e t h i n gt h a ti t
wasn’t. (Consumer 6)
Table 3 Participant Demographics
ID # Age Sex Education Experience with NHPs
1
1 25 F Post-secondary Work at HFS
2 28 F Health care professional NHP training
3 43 M High school None
4 24 F Post-secondary None
5 31 F Post-secondary None
6 29 F Post secondary None
7 42 F Post- secondary None
8 36 F Health professional NHP training
9 38 F High school None
10 28 F Post- secondary Worked at HFS
11 22 F High school None
12 34 F Post- secondary None
1Experience with NHPs was only described if it was beyond a lay level of
knowledge.
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Participants’ perceptions of the severity and seriousness
of their ADRs appeared to influence their behaviour.
Most participants confused the meaning of severe
and serious, and used them interchangeably. If they per-
ceived the reactions to be mild and/or non-serious,
they would generally attempt to mitigate the symptoms
independently. Participants claimed that if their
reactions had been severe, they would be more likely
to seek help or support with managing NHP-related
ADRs:
Question: What would make you more likely to talk
to someone about your reaction?
I suppose a cardiac event, like, for sure you would
want to tell somebody about that. I think that would
be significant. If you broke out into a rash, you
should probably tell somebody about that. If a pro-
duct, you know, made you nauseous or dizzy or
something like that, you might want to mention that
to somebody as well. (Consumer 7)
If the adverse event is mild then it just won’t
come up, but if it is severe and it’s an emergency
situation or if it has ongoing repercussions in health
[i.e., serious] then it’s vital that they be disclosed.
(Consumer 5)
I guess if it was a more severe reaction or if it hadn’t
cleared up ... [then I’d] go the hospital or something
like that. (Consumer 1)
Interestingly, some participants who experienced what
they defined as severe ADRs still did not report the
reaction to anyone or seek advice. This suggests that
there may be a difference between how consumers say
Table 4 Participant Reactions and Behaviours
ID
#
Product Reason for
taking NHP
Self
prescribed
ADR
1 Severity
1,2 Outcome Reporting
Behaviour
1 Stress relief supplement
(ingredients include L-theanine)
For
alertness/
Stress
Self
prescribed
Rash Moderate Recovered with
OTC treatment
Reported to PHM,
manufacturer via
HFS
2 Fish oil For health
maintenance
Self
prescribed
Rash Mild Recovered after
d/c
Reported to CAM
3 Weight loss product ingredients
unknown)
For weight
loss
Self
prescribed
Stimulation, irritability,
road rage
Severe Recovered after
d/c
Report to f/f, HFS
4 Digestive enzymes (ingredients
include amylase, protease, lipase)
For digestive
concerns
Self
prescribed
Stomach pain, bloating,
heartburn
Moderate Re-challenged,
Recovered after
d/c
Did not report
5 1. Herbal cleanse
2. [Wished not to disclose
product type or name]
1. Cleansing
product
2. For
energy
1. Self
prescribed
2. Self
prescribed
1. flatulence, bowel
urgency, stomach
discomfort
2. anxiety, depression,
nervousness, nausea
1. moderate
to severe
2. moderate
to severe
1. recovered after
d/c
2. recovered after
d/c
1. Did not report
2. Contacted
manufacturer
61 . Ginkgo biloba
2. weight loss product
3. St. John’s wort
1. for
memory
2. for weight
loss
3. for mood
1. Self
prescribed
2. Self
prescribed
3. Self
prescribed
1. sweating
2. shaky, disoriented
3. photosensitivity
1. mild
2. severe
3. mild
1. recovered after
d/c
2. recovered after
d/c
3. recovered after
d/c
1. Did not report
2. Did not report
3. Did not report
7 Valerian For sleep Self
prescribed
Agitated, unsettled Moderate Recovered after
d/c
Did not report
8 Fish oil For health
maintenance
Self
prescribed
Rash Mild Recovered after
d/c
Report to CAM, f/f,
manufacturer
9 Thyroid glandular For weight
loss
MD
prescribed
Headache, nausea Severe Changed dose Report to MD
10 Multi-vitamin For health
maintenance
Self
prescribed
Nausea, vomiting Severe Re-challenged,
recovered after
d/c
Report to f/f
11 Weight loss product For weight
loss
Self
prescribed
Heartburn Mild to
moderate
Re-challenged,
recovered after
d/c
Report to f/f
12 Melatonin For sleep Self
prescribed
Groggy, uncoordinated Mild to
moderate
Recovered after
d/c
Did not report
1 some participants experienced reactions to more than one product;
2 severity is classified according to patient definition of severity; d/c = discontinuation; CAM
= complementary and alternative medicine practitioner; MD = medical doctor; PHM = pharmacist; F/f = friends and family; HFS = health food store
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cally, more severe or serious reactions would result in
an increased likelihood of reports.
Barriers and enablers to reporting
Participants outlined a range of reasons for not report-
ing. Barriers to reporting included: taking responsibility
for self prescribing, lack of awareness of who to tell and
the specific reporting process, perceived complexity of
the reporting process and fear of losing access to NHPs.
Similarly, the main enablers to reporting were feeling
comfortable with the person with whom they shared
their ADR experience and knowing that one could or
should report the ADR.
Many participants believed that since they had inde-
pendently made the decision to take NHPs, they also
had a responsibility to “deal with” the negative conse-
quences of that decision on their own. Consumers’ deci-
sions regarding how to respond to NHP-related ADRs
therefore depended largely on whether or not they
believed themselves to be responsible for the decision to
initiate NHP use without advice from a healthcare prac-
titioner:
We often combine products in a way that it can be
detrimental to our health and I believe that this
adverse reaction had to do with that more than the
product itself... so that just has to do with irresponsi-
ble consumption... So yeah, the adverse reaction is
my problem. (Consumer 5)
I mean I told my doctor about the [pharmaceutical
medication] because he was the person who pre-
scribed it to me. I didn’t tell anybody about the
[ N H P ]b e c a u s en o b o d yp r e s c r i b e di tt om es oI
thought, well, I guess I didn’t think that I should tell
anyone. I think I just didn’t think I should tell any-
body! (Consumer 7)
Id i d n ’t [report] because there wasn’t anyone really
to tell about it because I wasn’ts e e i n gad o c t o ra t
the time and I was more sort of trying things on my
own. (Consumer 10)
A key reason why consumers experiencing NHP-
related suspected ADRs did not report was because they
did not know who to talk to. In part, this was because
they had self-purchased the NHP and didn’t think there
was anyone to turn to. In some cases, the decision not
t od i s c u s st h e i re x p e r i e n c e sw i t ho t h e r sw a sb e c a u s e
they didn’t feel that they could confide in their health
care providers (often physicians). These participants per-
ceived that their health care providers would disapprove
of their use of NHPs, or not give adequate attention to
their concerns:
After I figured out what was going on I knew it was
me doing it to me, by choosing to take it, I knew
that that I was the cause of it but my doctor
wouldn’t do anything about it and she would just
kind of blow it off so, there would be no point in
taking it to her because I just didn’t have a therapeu-
tic relationship with her. (Consumer 10)
Well our family doctor is, sort of, you know, she
l i k e st ot a k et h i n g sl i g h t l y ,s oi nas e n s es o m e t i m e s
I feel like I shouldn’t even go so I should wait things
out before I talk to her about them because I feel
like she’s just going to say the same thing to me,
like, oh well, whatever, just go home and have some
rest and it will be okay. It’s a matter of, there hasn’t
been the time, the time has not been permitted to
go into much detail about it. (Consumer 7)
These quotes illustrate the challenges that many parti-
cipants had with their conventional medical practi-
tioners, especially when discussing issues associated with
NHPs. Most were of the opinion that their healthcare
providers (most often physicians and pharmacists)
would not support their decisions to try NHPs and this
resulted in a lack of communication about suspected
NHP-related ADRs:
Her [the pharmacists’] initial reaction when I told
her [that I had had a reaction to an NHP], was like,
there’s no need for me to discuss this any further.
(Consumer 1)
I’ve had a doctor tell me that I [the doctor] don’t
really believe in all that [NHP] stuff. So I personally
wouldn’t bother telling them about my adverse
effects. I’d just tell the naturopath, or the health
food store. (Consumer 4)
If participants thought their friends and family would
understand their decisions to use NHPs, they might
share their NHP-related ADR experiences with people
in their social network. Other participants, who wanted
reassurance or guidance about their experiences, dis-
cussed approaching other resources such as retailers at
the location where they purchased NHPs such as phar-
macists and health food store personnel. However, over-
all, they seemed not to have strong relationships with
their pharmacists, which negatively affected their likeli-
hood of reporting ADRs to pharmacists:
Let’s say that I buy something from [drug store
name]. If I’m not happy with it, generally if I can’t
return it. ... I probably wouldn’t take it back or take
any type of concern to that particular store because
I feel like the people that work there would not
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deal with that kind of thing. They have so many
other things that they’re selling in that store. It’s just
not an open and friendly environment to bring stuff
to. With regards to smaller stores, smaller health
food stores, it’s an environment where the owner
always tries to have a good customer relationship.
(Consumer 10)
In some cases, participants described a general distrust
of conventional medicine which appeared to be driving
their use of NHPs in the first place and was likely a key
factor in why they did not turn to conventional health
care providers for help. This also seemed to be related
to perceptions of conventional medicine having much
higher risk than NHPs which were thought to be safe:
I come from a family with immensely little trust of
any sort of medical doctors ... especially conventional
medical practitioners so I try avoid medicines in
general (Consumer 6)
I think in general natural health products are safer
to take. You can take them for a longer period of
time, you can take them for many different condi-
tions as well. (Consumer 8)
Participants tended to feel comfortable with their
health food store personnel and often described good
relationships with the staff working in these retail set-
tings. Consumers reported reliance on the health food
store staff for information and feeling comfortable talk-
ing to them about side effects or problems with their
products:
I would trust [staff] more from a health food store
because they do - usually the owners of the store
have good information and have some knowledge
whereby the pharmacies would have nothing, and a
pharmacist would probably bash it down anyway!
(Consumer 3)
Besides health food stores, participants also felt com-
fortable contacting the NHP manufacturer in situations
of suspected ADRs.
I contacted [the manufacturer via the health food
store]... I just wanted to tell them, in case anyone
else had the same thing. That way the more people
who talk about it the more chances that they’ll actu-
ally do something. (Consumer 1)
Because I was satisfied with the product and then
something changed [from the last time I used it],
and I was extremely unsatisfied with it, I felt the
need to address that. (Consumer 5)
I feel like I did have resources and I certainly fol-
lowed up on them [with the manufacturer]... I’mn o t
happy with the answer that I was provided with.
I have taken other products from this company and
it’s not that I don’t feel like they manufacture unsafe
products, I just don’t particularly agree with how
they handled this particular situation. (Consumer 8)
A related barrier to reporting directly to Health Cana-
da’s ADR reporting system was that participants did not
always know that reporting their suspected ADR to
Health Canada was an option. Typical of this was the
response of one respondent who stated he was not
familiar with the process for reporting. He went on to
add, “. . .T h e ys h o u l dm a k ep e o p l em o r ea w a r eo fi t ”.
(Consumer 3)
For participants who knew that reporting to Health
Canada was an option, another barrier was the perceived
complexity of the reporting process online. For example,
the following participant knew that online reporting to
Health Canada was encouraged but still had trouble
navigating through the system.
I was trying to follow the different links [to report
online] but there were so many layers, maybe three
or four layers, and you had to consent, you know,
this is for information purposes and it wasn’tv e r y
easy to do, I have to say. (Consumer 2)
Another barrier to reporting, described by several par-
ticipants, was the fear that the implicated product would
be withdrawn from the market, which would limit or
prevent access to it in the future.
It is the only product that I’ve found effective for my
health condition. It is something that I feel when
used properly it doesn’t cause an adverse reaction.
I think that [reporting] jeopardizes the status of pro-
ducts that may be required for certain health condi-
tions. (Consumer 7)
It’s totally inconsistent as to how I can even access
it, which is a problem... hence my concerns about it
being pulled from the market. (Consumer 6)
Discussion
Participants in this study had all experienced what they
perceived to be suspected ADRs associated with NHPs.
The products were usually self-prescribed and most par-
ticipants decided either to handle the situation on their
own or, less commonly, to discuss it with someone with
whom they felt comfortable. The trusted person was
typically thought to be someone working in a health
food store or the company that had manufactured the
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care provider. Participants either reported to the manu-
facturer directly or via the health food store. Other
p a r t i c i p a n t sw h od i dn o tr e p o r ts a i dt h a ti ft h e i rc o n -
cerns were more pressing, they would feel more comfor-
table contacting the health food store personnel rather
than their conventional health provider. Participants’
responses to experiencing NHP-related suspected ADRs
were based partly on their perceptions of the severity
and seriousness of the reactions, reflecting the impor-
tance of individual perceptions in reporting ADRs.
Participants identified experiences as suspected ADRs
and linked them to use of particular NHPs. In many
cases, the processes participants used to do this were
systematic and to some extent reflected some of the
strategies used by healthcare professionals in their
response to a patient reporting to them a suspected
ADR, as well as the evaluative processes used by phar-
macovigilance experts to assess causality. Despite consu-
mers’ lack of background medication knowledge, this
process was similar to protocols used by health profes-
sionals to investigate potential ADRs i.e., the likelihood
that symptoms are caused by a specific product. For
example, participants considered the temporal relation-
ship between product use and symptom appearance, the
effects of discontinuing the product (de-challenge), re-
challenging with the product, and other changes in their
medication regimen [18,19].
In many cases, participants explained that they did not
report the NHP-related suspected ADRs to Health Cana-
da’s ADR reporting system because they were unaware
that such things could be reported and/or they did not
know where to report. Most national ADR reporting
schemes do not allow reports direct from consumers
because of concerns about low-quality reports (e.g., miss-
ing important clinical information) and about the potential
for obscuring important signals due to large numbers of
reports [19,20]. Although Health Canada has always
accepted direct reporting of suspected ADRs by consu-
mers, this is not widely advertised and consumer reports
are adjudicated separately from reports submitted by
healthcare providers. In Canada, consumer reports are
usually used to clarify or provide additional support for
suspected ADRs (or signals) raised from healthcare provi-
der reports.
Our data suggest that a lack of awareness about the
opportunity for direct consumer reporting is limiting
reporting by consumers. However, fear about what hap-
pens after submission of a consumer ADR report and
distrust of Health Canada’s regulatory response and its
impact on the NHP market are also barriers for consu-
mers. These concerns may explain why participants
appeared to prefer reporting an NHP-related suspected
ADR to someone they trusted - in this case health food
store personnel and NHP companies.
A key finding was that the relationship between con-
sumers and their service providers can act as a barrier
or facilitator to reporting of suspected ADRs. Other
research suggests that participants perceive high quality
healthcare to include recognition of their status as
informed patients and acknowledgement of their perso-
nal worth [21,22]. In the present study, participants felt
that their physicians or pharmacists would ignore their
concerns or question their values and beliefs in NHPs.
This type of response negatively impacts the partici-
pants’ abilities to maintain open and honest relation-
ships with their healthcare providers. Participants who
d i dn o tt r u s tt h e i rc o n v e n t i onal practitioners to respect
their NHP-related choices sought out other advisors; in
this study, that often included health food store staff.
This is problematic though, as Canadian health food
stores are not regulated, there are no common standards
for employee training and the quality of advice given
may be variable. In addition, health food store staff gen-
erally have no knowledge of the ADR reporting systems
[23-25] and, therefore, reporting suspected ADRs to
health food store staff is not likely to lead to the report
being captured by the passive surveillance system.
The finding that some consumers report adverse events
to manufacturers is important in that it provides another
avenue through which Health Canada can access adverse
event information. Manufacturers are responsible for
reporting this information back to Health Canada. It is
therefore important to ensure that this avenue of com-
munication is robust. More research is needed in this
area because NHPs are currently lightly regulated com-
pared to pharmaceuticals. Competing interests and com-
munication systems within the manufacturing industry
may cause further complications to safety monitoring.
Under-reporting to passive surveillance systems is not
new [12,26-29], however NHP ADR monitoring has addi-
tional complexities beyond the concerns of pharmaceuti-
cal post marketing surveillance. In particular, the
consumer’s comfort level with their health care providers
impacts on their inclination to report use and experience
of ADRs associated with NHPs. In addition, the chance
of consumers contacting health food stores and manufac-
turers has not been discussed in pharmaceutical ADR lit-
erature. These issues need to be further examined in
order to improve safe use of these products.
Limitations
The study has several limitations that merit explanation.
Interviews were only conducted with people who had
already decided that their suspected ADR was linked to
their use of a particular NHP. We were unable to
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who experienced suspected ADR(s) while taking NHPs,
but who had decided that these products were not asso-
ciated with their ADR(s). In addition, due to the diffi-
culty in recruiting participants, there was no time limit
related to when the ADR was experienced. Some partici-
pants had experienced their reaction a few years before
the interview. Based on the high level of detail and the
emotional impact of the reactions experienced more
than 3 months prior to the interview, these were signifi-
cant events in the participants’ lives that they remem-
bered clearly, although recall bias cannot be completely
discounted. Also, the demographic profile of the study
participants is not representative of that of the Canadian
population: our sample was highly educated and, in
many cases, very familiar with NHPs, so further research
with less well educated and less knowledgeable NHPs
users (assuming they could be recruited) may be war-
ranted. Given the high levels of education, it is likely
that our sample was more knowledgeable about NHPs
and options for reporting than those we were unable to
interview. Despite the limited sample, the behaviours of
the participants highlight important deficiencies in ADR
reporting in a knowledgeable population [30]. The diver-
sity of the products used and types of suspected ADRs
enabled analysis of a range of experiences and saturation
in the key themes as one would expect in this type of
exploratory study.
Conclusion
Consumers’ descriptions of their NHP-related ADR
experiences and reporting behaviours highlight several
issues related to the current safety monitoring system.
Few consumers know about the reporting opportunities,
even fewer report directly via the Health Canada vigi-
lance system. In addition, consumers fail to tell their
physicians or pharmacists about these suspected reac-
tions, which means that the current passive surveillance
system is not capturing the majority of NHP-related
suspected ADRs. Our study provides some explanations
as to why this is occurring.
Consumers in our study who have experienced an
NHP-related suspected ADR are unlikely to discuss
their experiences with a health professional often
because they self-prescribed the product and thus feel a
need to “take responsibility” for the decision to use the
NHP. This is compounded by consumers’ perceptions
that conventional healthcare providers will not under-
stand their decisions to use NHPs and thus fear that
they will not be supported to address the NHP-related
suspected ADR. This study highlights the need for
health professionals to be open-minded about their
patients’ choices regarding NHPs and the importance of
developing good communication around NHPs so that
patients will be comfortable sharing suspected ADR
experiences. While under-reporting is a well established
challenge of passive surveillance systems, the problems
associated with NHP ADR monitoring are more com-
plex than those associated with pharmaceutical drugs.
This study has identified several issues with implica-
tions for NHP safety monitoring. First, healthcare provi-
ders must be open to discussing NHPs with their
patients, recognizing that many patients (likely at least
half) may be using these products. Previous research
suggests that initiation of NHP dialogue should occur at
the first stages of patient contact, perhaps during regular
medicine history taking [31]. It is also important to
recognize that while disclosure of NHP use is essential,
successful communication does not mean that health-
care practitioners have to approve of patients’ choices
[32]. In the case of NHP-related ADRs, communication
of this type seems essential to enabling a trusting rela-
tionship. Our findings suggest that only when healthcare
practitioners are seen as sources of information and
support will consumers disclose their concerns when
experiencing an NHP-related ADR.
This study also found that consumers are generally
unaware that they are able to report directly to Health
Canada and therefore, there is a need for initiatives to
raise awareness among NHP users of this avenue for
reporting suspected NHP ADRs. Spontaneous reporting
systems are at present the mainstay of detecting signals
of safety concerns associated with NHPs [12]. If sus-
pected ADRs associated with NHPs do not reach the
system, either through direct patient reporting or
through reporting from healthcare professionals, then
the detection of safety concerns may be missed or
delayed. This has important implications for protection
of the public health.
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